Q1 Earnings Forecast for BHST Issued By HC Wainwright

BioHarvest Sciences Inc. (NASDAQ:BHST) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of BioHarvest Sciences in a research note issued to investors on Tuesday, April 14th. HC Wainwright analyst A. Dayal forecasts that the company will earn ($0.04) per share for the quarter. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at $0.07 EPS and FY2028 earnings at $0.37 EPS.

Several other equities research analysts have also issued reports on BHST. Roth Mkm started coverage on shares of BioHarvest Sciences in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BioHarvest Sciences presently has a consensus rating of “Hold” and a consensus price target of $12.50.

BioHarvest Sciences Trading Up 0.7%

BioHarvest Sciences stock opened at $4.30 on Thursday. The firm has a 50 day moving average of $4.44 and a 200 day moving average of $6.24. The firm has a market capitalization of $84.35 million, a price-to-earnings ratio of -7.05 and a beta of 1.16. BioHarvest Sciences has a 12-month low of $4.10 and a 12-month high of $12.80. The company has a current ratio of 3.97, a quick ratio of 3.38 and a debt-to-equity ratio of 0.10.

Institutional Investors Weigh In On BioHarvest Sciences

Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in BioHarvest Sciences during the 4th quarter valued at approximately $60,000. Geode Capital Management LLC purchased a new stake in BioHarvest Sciences during the 4th quarter valued at approximately $61,000. HRT Financial LP purchased a new stake in BioHarvest Sciences during the 4th quarter valued at approximately $75,000. Marshall Wace LLP purchased a new stake in BioHarvest Sciences during the 4th quarter valued at approximately $110,000. Finally, Quadrature Capital Ltd purchased a new stake in BioHarvest Sciences during the 4th quarter valued at approximately $140,000.

Key Headlines Impacting BioHarvest Sciences

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: HC Wainwright now models a FY2026 loss of ($0.22) and quarter-by-quarter 2026 EPS of ($0.04), ($0.09), ($0.05) and ($0.04). Those FY2026 figures imply a much smaller loss than the consensus (-$0.80), which reduces near-term financing and path‑to‑profit concerns. MarketBeat Report
• Neutral Sentiment: The note gives detailed quarter-level guidance for 2026 and projects positive earnings in later years (FY2027 and beyond in HC Wainwright’s model), providing clearer visibility on the firm’s expected cadence to profitability — useful but not a guaranteed outcome. MarketBeat Report
• Negative Sentiment: HC Wainwright cut long‑term estimates: FY2027 from $0.22 to $0.07, FY2028 from $0.55 to $0.37 and FY2029 from $1.00 to $0.80. Those downgrades reduce the company’s growth trajectory and likely lower valuation assumptions, which is the main negative driver for today’s pullback. MarketBeat Report

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.